tisolagiline

KDS2010 (tisolagiline) is a highly selective and reversible small molecule inhibitor of monoamine oxidase B (MAO-B). It is being developed as an oral therapy for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Unlike traditional irreversible MAO-B inhibitors, KDS2010 offers improved selectivity for MAO-B over MAO-A (12,500-fold), reversibility of inhibition, and a favorable safety profile. Its mechanism involves blocking aberrant GABA and hydrogen peroxide production in reactive astrocytes by inhibiting MAO-B activity. This reduces neuronal inhibition, neuroinflammation, and neurodegeneration while promoting neuroregeneration. Preclinical studies have shown significant neuroprotective and anti-neuroinflammatory effects in animal models of Parkinson’s disease and Alzheimer’s disease. Clinical trials are ongoing to evaluate its efficacy in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. Developed by Scilex Holding Company.

Other names

KDS2010KDS-2010KDS 2010tisolagiline